Meir Bialer
#165,996
Most Influential Person Now
Researcher
Meir Bialer's AcademicInfluence.com Rankings
Meir Bialercomputer-science Degrees
Computer Science
#9954
World Rank
#10442
Historical Rank
Computational Linguistics
#2478
World Rank
#2502
Historical Rank
Machine Learning
#4494
World Rank
#4544
Historical Rank
Artificial Intelligence
#4852
World Rank
#4915
Historical Rank
Download Badge
Computer Science
Why Is Meir Bialer Influential?
(Suggest an Edit or Addition)Meir Bialer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Key factors in the discovery and development of new antiepileptic drugs (2010) (456)
- Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII) (2007) (439)
- Development of new antiepileptic drugs: challenges, incentives, and recent advances (2007) (320)
- Therapeutic Drug Monitoring of the Newer Antiepileptic Drugs (2003) (317)
- Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) (2004) (281)
- Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX) (2009) (200)
- Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI) (2013) (200)
- Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV) (1999) (190)
- The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors (2004) (188)
- Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI) (2002) (177)
- Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs (1993) (171)
- Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X) (2010) (166)
- The Clinical Pharmacokinetics of the Newer Antiepileptic Drugs (1996) (165)
- Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII) (2015) (164)
- Pharmacokinetic Interactions of Topiramate (2004) (156)
- Effect of Topiramate or Carbamazepine on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Healthy Obese and Nonobese Female Subjects (2003) (150)
- Why are antiepileptic drugs used for nonepileptic conditions? (2012) (149)
- Pharmacokinetics and drug interactions of eslicarbazepine acetate (2012) (147)
- Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V) (2001) (146)
- Valproate decreases inositol biosynthesis (2004) (131)
- Chemical properties of antiepileptic drugs (AEDs). (2012) (122)
- Eslicarbazepine Acetate: A Double‐blind, Add‐on, Placebo‐controlled Exploratory Trial in Adult Patients with Partial‐onset Seizures (2007) (121)
- New antiepileptic drugs that are second generation to existing antiepileptic drugs (2006) (114)
- Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development (2018) (111)
- Valproic acid: Second generation (2011) (106)
- Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) (2017) (97)
- Comparative Pharmacokinetics of the Newer Antiepileptic Drugs (1993) (96)
- Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers (1994) (96)
- Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase (2005) (95)
- Enantioselective pharmacokinetics of 10‐hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects (1999) (90)
- Clinical Pharmacology of Valpromide (1991) (80)
- Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue? (2007) (79)
- The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium (2011) (75)
- Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. (2011) (67)
- Extended-Release Formulations for the Treatment of Epilepsy (2007) (67)
- Pharmacokinetic and Metabolic Investigation of Topiramate Disposition in Healthy Subjects in the Absence and in the Presence of Enzyme Induction by Carbamazepine (2005) (66)
- The antiepileptic and anticancer agent, valproic acid, induces P‐glycoprotein in human tumour cell lines and in rat liver (2006) (66)
- Pharmacokinetics of cannabidiol in dogs. (1988) (65)
- New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? (2003) (64)
- Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid (1998) (63)
- Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients (2002) (62)
- A new derivative of valproic acid amide possesses a broad‐spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage (2012) (62)
- Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain (2005) (62)
- Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development (2018) (61)
- Pharmacokinetics of Levetiracetam and Its Enantiomer (R)‐α‐ethyl‐2‐oxo‐pyrrolidine acetamide in Dogs (2001) (59)
- Topiramate and Lamotrigine Pharmacokinetics during Repetitive Monotherapy and Combination Therapy in Epilepsy Patients (2003) (56)
- Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels (2004) (56)
- New CNS-active drugs which are second-generation valproic acid (2003) (56)
- Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability (2009) (55)
- Progress report on new antiepileptic drugs A summary of the Second Eilat Conference (1995) (51)
- Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. (2005) (51)
- Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2‐Pyrrolidinone N‐Butyric Acid, and Its Enantiomer (R)‐α‐ethyl‐oxo‐pyrrolidine Acetamide in a Mouse Model of Teratogenicity (2003) (50)
- Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. (2005) (49)
- Anticonvulsant Profile of Valrocemide (TV1901): A New Antiepileptic Drug (2001) (48)
- Does carbamazepine have a narrow therapeutic plasma concentration range? (1998) (48)
- Metabolism and pharmacokinetics of T-2 toxin and related trichothecenes. (1993) (47)
- Enantioselective analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. (2000) (47)
- Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications (2020) (47)
- Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. (2007) (46)
- The Pharmacokinetics and Interactions of New Antiepileptic Drugs: An Overview (2005) (44)
- Analysis of Topiramate and Its Metabolites in Plasma and Urine of Healthy Subjects and Patients With Epilepsy by Use of a Novel Liquid Chromatography–Mass Spectrometry Assay (2003) (42)
- The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans (2007) (41)
- Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy (1997) (40)
- Alpha-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. (2009) (39)
- The Effects of Central Nervous System-Active Valproic Acid Constitutional Isomers, Cyclopropyl Analogs, and Amide Derivatives on Neuronal Growth Cone Behavior (2007) (39)
- Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes (1994) (39)
- Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. (2000) (38)
- Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials (2020) (38)
- Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference (1996) (37)
- Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers (2013) (36)
- Structure-pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. (1990) (36)
- Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. (2004) (35)
- Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain (2005) (35)
- Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. (1996) (35)
- Pharmacokinetics of the New Antiepileptic and CNS Drug RWJ‐333369 Following Single and Multiple Dosing to Humans (2006) (34)
- Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development (2020) (34)
- Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development (2020) (33)
- Amidic modification of valproic acid reduces skeletal teratogenicity in mice. (2004) (33)
- Anticonvulsant Profile and Teratogenicity of N‐methyl‐tetramethylcyclopropyl Carboxamide: A New Antiepileptic Drug (2002) (33)
- Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs (1992) (32)
- Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity (1989) (32)
- Pharmacokinetic-Pharmacodynamic Relationships of (2S,3S)-Valnoctamide and Its Stereoisomer (2R,3S)-Valnoctamide in Rodent Models of Epilepsy (2003) (31)
- Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. (2009) (30)
- Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma. (1984) (30)
- A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus (2013) (29)
- Application of a variance-stabilizing transformation approach to linear regression of calibration lines. (1990) (29)
- Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research (2020) (29)
- Pharmacokinetic Interaction Study between the New Antiepileptic and CNS Drug RWJ‐333369 and Carbamazepine in Healthy Adults (2006) (28)
- Stereoselective Pharmacokinetics and Pharmacodynamics of Propylisopropyl Acetamide, a CNS-Active Chiral Amide Analog of Valproic Acid (1999) (28)
- A total synthesis of distamycin a, an antiviral antibiotic (1978) (28)
- Comparative steady‐state pharmacokinetic evaluation of immediate‐release topiramate and USL255, a once‐daily extended‐release topiramate formulation (2013) (27)
- Genetic Polymorphism of CYP2D6 and CYP2C19 Metabolism Determined by Phenotyping Israeli Ethnic Groups (2000) (27)
- In Vivo Study of the Effect of Valpromide and Valnoctamide in the Pilocarpine Rat Model of Focal Epilepsy (2000) (27)
- A Comparative Study of the Effect of Carbamazepine and Valproic Acid on the Pharmacokinetics and Metabolic Profile of Topiramate at Steady State in Patients with Epilepsy (2005) (26)
- Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid (2010) (25)
- Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. (1999) (25)
- Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. (2010) (25)
- Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents (2003) (25)
- Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects (2004) (25)
- Criteria to Assess In Vivo Performance and Bioequivalence of Generic Controlled‐Release Formulations of Carbamazepine (1998) (24)
- How did phenobarbital’s chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? (2012) (24)
- Can we develop improved derivatives of valproic acid? (1994) (23)
- Interlaboratory Variability in the Quantification of New Generation Antiepileptic Drugs Based on External Quality Assessment Data (2003) (23)
- Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous administration in dogs. (1986) (23)
- Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS‐active derivative of valproic acid with low teratogenic potential (2014) (23)
- Generic Products of Antiepileptic Drugs: A Perspective on Bioequivalence, Bioavailability, and Formulation Switches Using Monte Carlo Simulations (2013) (23)
- Comparative pharmacokinetic analysis of USL255, a new once‐daily extended‐release formulation of topiramate (2011) (23)
- Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. (1985) (23)
- Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide (1996) (22)
- Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine (1998) (22)
- Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study. (2012) (22)
- sec‐Butyl‐propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon‐induced status epilepticus in rats (2014) (22)
- New Antiepileptic Drugs Currently in Clinical Trials: Is There a Strategy in Their Development? (2002) (22)
- Disposition of sulfadimethoxine in cattle: inclusion of protein binding factors in a pharmacokinetic model. (1981) (21)
- Structure-activity relationships of pyrrole amidine antiviral antibiotics. 2. Preparation of mono- and tripyrrole derivatives of congocidine. (1980) (21)
- Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. (2012) (21)
- Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine (1995) (21)
- An Interaction Study Between the New Antiepileptic and CNS Drug Carisbamate (RWJ‐333369) and Lamotrigine and Valproic Acid (2007) (20)
- A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans (1985) (20)
- Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase (2017) (20)
- Pharmacokinetics and Antiepileptic Activity of Valproyl Hydroxamic Acid Derivatives (1997) (19)
- New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins. (1986) (19)
- Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. (2013) (19)
- Valnoctamide and sec‐butyl‐propylacetamide (SPD) for acute seizures and status epilepticus (2013) (19)
- The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus (2015) (19)
- Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. (1999) (18)
- Absolute configuration of the four stereoisomers of valnoctamide (2-ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug (1999) (18)
- Pharmacokinetic Model of Circulating Covalent Aggregates of Insulin (1988) (18)
- Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. (1988) (18)
- Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug (2006) (18)
- A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond (2020) (17)
- Pharmacokinetics of valproic acid in volunteers after a single dose study. (1985) (17)
- The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations (2020) (17)
- Structure--activity relationships of pyrrole amidine antiviral antibiotics. 1. Modifications of the alkylamidine side chain. (1979) (17)
- Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. (1990) (16)
- Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice (2015) (16)
- Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs. (1988) (15)
- Pharmacokinetics of valpromide in dogs after various modes of administration. (1984) (15)
- Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice (2003) (15)
- Pharmacokinetic/Pharmacodynamic Basis of Controlled Drug Delivery (1987) (15)
- Polycomb homologs are involved in teratogenicity of valproic acid in mice. (2004) (15)
- Identification of urinary metabolites of cannabidiol in the dog. (1990) (14)
- Pharmacokinetics of urinary metabolites of cannabidiol in the dog (1990) (14)
- A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs (1983) (14)
- Quantitative assessment of the switchability of generic products. (2013) (14)
- Structure-activity relationships of pyrrole amidine antiviral antibiotics III: preparation of distamycin and congocidine derivatives based on 2,5-disubstituted pyrroles. (1980) (14)
- Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs. (1990) (14)
- Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. (2021) (14)
- Structure‐Pharmacokinetic‐Pharmacodynamic Relationships of yV‐Alkyl Derivatives of the New Antiepileptic Drug Valproyl Glycinamide (1999) (14)
- Structure Activity Relationship of Human Microsomal Epoxide Hydrolase Inhibition by Amide and Acid Analogues of Valproic Acid (2000) (13)
- Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII) (2017) (13)
- Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans (1987) (13)
- PHARMACOKINETICS AND METABOLISM OF A NEW POTENT ANTIEPILEPTIC DRUG, 2,2,3,3-TETRAMETHYCYCLOPROPANECARBONYLUREA, IN RATS (2005) (12)
- Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. (1982) (12)
- Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide (1992) (12)
- Clinical pharmacology of parenteral use of antiepileptic drugs (2007) (12)
- sec‐Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain (2017) (12)
- Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. (1984) (12)
- Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen (1995) (12)
- Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. (1998) (12)
- Serum protein binding of a new oral cephalosporin, CL 284,635, in various species. (1986) (11)
- Pros and Cons for the Development of New Antiepileptic Drugs (2002) (11)
- Anticonvulsant profile and teratogenicity of 3,3‐dimethylbutanoylurea: A potential for a second generation drug to valproic acid (2008) (11)
- Comparative Pharmacokinetic and Pharmacodynamic Analysis of Phthaloyl Glycine Derivatives with Potential Antiepileptic Activity (1994) (11)
- Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers (2004) (11)
- Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. (1999) (11)
- Stability of diltiazem in different biological fluids (1991) (11)
- The Disposition of Valproyl Glycinamide and Valproyl Glycine in Rats (1997) (11)
- Third International Congress on Epilepsy, Brain and Mind: Part 1 (2015) (11)
- A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes (1980) (11)
- sec-Butylpropylacetamide (SPD) has antimigraine properties (2016) (11)
- Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice (2018) (10)
- Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives (1999) (10)
- Comparative Stereoselective Pharmacokinetic Analysis of 10‐Hydroxycarbazepine After Oral Administration of its Individual Enantiomers and the Racemic Mixture to Dogs (2000) (10)
- Metabolism of a new antiepileptic drug, N-methyl-tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites (2004) (10)
- Pharmacokinetic analysis and antiepileptic activity of two new isomers of N‐valproyl glycinamide (1997) (10)
- Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. (2006) (10)
- Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives. (2008) (9)
- Pharmacokinetics of T-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, T-2 toxin, in dog. (1987) (9)
- The disposition of valpromide in rats and the isolated perfused rat liver. (1990) (9)
- The relationships between half‐life (t1/2) and mean residence time (MRT) in the two‐compartment open body model (2004) (9)
- Relation between absorption half-life values of four novel sustained-release dosage forms of valproic acid in dogs and humans. (1986) (9)
- Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid (2011) (9)
- Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations. (1995) (9)
- Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus (2009) (9)
- Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects (2017) (9)
- Pharmacokinetic analysis of ester prodrugs of valproic acid. (1992) (9)
- Comparative efficacy of valnoctamide and sec‐butylpropylacetamide (SPD) in terminating nerve agent–induced seizures in pediatric rats (2019) (9)
- Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide — Amide derivatives of valproic acid (2015) (9)
- Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide (2017) (8)
- Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS‐active carbamate derivatives of valproic acid (2014) (8)
- Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma. (1985) (8)
- Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide (2008) (8)
- Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic Acid (1991) (8)
- Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. (1984) (8)
- Identification of metabolites of the 1",1"-dimethylheptyl analogue of cannabidiol in rat and dog in vivo. (1990) (8)
- Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. (1996) (7)
- Bioequivalence and switchability of generic antiseizure medications (ASMs): A re‐appraisal based on analysis of generic ASM products approved in Europe (2021) (7)
- Stereoselective Pharmacokinetic Analysis of Valnoctamide, a CNS-Active Chiral Amide Analogue of Valproic Acid, in Dogs, Rats, and Mice (2000) (7)
- The structural requirements for the design of antiepileptic-glycine derivatives (1999) (7)
- Effect of sustained release on the pharmacokinetics of valproic acid in the dog (1984) (7)
- Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder. (2013) (7)
- Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue (2012) (7)
- A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study (1986) (7)
- Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. (1987) (6)
- Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice. (2009) (6)
- Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus. (2016) (6)
- A randomized, double‐blind, placebo‐ and risperidone‐controlled study on valnoctamide for acute mania (2017) (6)
- Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development (2022) (6)
- Rapid high-performance liquid chromatographic assay with pharmacokinetic applications for monitoring cannabidiol in plasma. (1987) (6)
- Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology (2009) (6)
- Valproic acid derivatives signal for apoptosis and repair in vitro. (2013) (6)
- Metabolism of cannabidiol by the rat (1991) (5)
- Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative (2019) (5)
- Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: evaluation of the teratogenic effects of its amide derivatives in NMRI mice. (2008) (5)
- Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. (1986) (5)
- Stereoselective Pharmacokinetic Analysis and Antiepileptic Activity of N-2-Hydroxypropyl Valpromide, a Central Nervous System–Active Chiral Valproylamide (2001) (5)
- An alternative method for calculating absorption and elimination rate constants in first-order processes: application to valproic acid (1983) (5)
- Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3‐tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid (2010) (5)
- Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide (2007) (5)
- The relationship between drug input and mean residence time in the body. (1986) (5)
- Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. (1987) (5)
- Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats (2013) (5)
- The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet (1991) (5)
- Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): A chiral stereoisomer of valproic acid urea derivative (2010) (4)
- Corrigendum to: ``Conference Report. Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference'' [Epilepsy Res. 25 (1996) 299] 1 PII of original article: S0920-1211(96)00081-2. 1 (1997) (4)
- Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. (1988) (4)
- Pharmacokinetics of carisbamate (RWJ‐333369) in healthy Japanese and Western subjects (2009) (4)
- Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid (1993) (4)
- Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy (2022) (4)
- Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? (2022) (4)
- Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development (2022) (4)
- Pharmacokinetic interaction between diltiazem and amiodarone in the dog. (1989) (4)
- Antiparasitic structure-activity relationships of congocidine derivatives. (1981) (4)
- Pharmacokinetic analysis of two new sustained‐release products of diltiazem designed for twice‐and once‐daily treatment (1994) (4)
- In vitro protein binding interaction studies involving cefixime (1988) (4)
- Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. (2016) (4)
- Novel treatment approaches and pediatric research networks in status epilepticus (2019) (3)
- Comments on the working group’s 2012 review of the Program (2012) (3)
- A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV) (2019) (3)
- STRUCTURE ELUCIDATION OF A CONDENSATION PRODUCT OF 4-AMINOPYRROLE DERIVATIVES AND DICYCLOHEXYLCARBODIIMIDE (1980) (3)
- Synthesis and Enantioselective Pharmacokinetic/Pharmacodynamic Analysis of New CNS-Active Sulfamoylphenyl Carbamate Derivatives (2021) (3)
- Isolation of a cigarette smoke fraction responsible for the inhibition of benzo[a]pyrene metabolism in the isolated perfused rabbit lung. (1984) (3)
- Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (Vss) utilizing model-independent approach. (2004) (3)
- Distamycin and Derivatives: The Pyrrole Amidine Antiviral Antibiotics (1984) (3)
- Special issue: Phenobarbital: the Centenary - 10th European Congress on Epileptology, London - October 1, 2012. Introduction. (2012) (3)
- Use of mean residence time to determine the magnitude of difference between rate constants and to calculate tmax in the Bateman equation (1999) (2)
- Phenotypic evaluation of CYP2C9 by way of phenytoin metabolic ratio (PMR) (2005) (2)
- Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans (2004) (2)
- Critical analysis of the discrepancy between V(beta) and V(ss) for drugs exhibiting different two-compartment disposition profiles. (2005) (2)
- Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. (1997) (2)
- Disposition of Progabide and Valproic Acid Following Intraperitoneal Administration in Rhesus Monkey (1984) (2)
- Dose-Dependent Pharmacokinetics of a New Oral Cephalosporin, Cefixime, in the Dog (1987) (2)
- Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs (1994) (2)
- STRUCTURE-ACTIVITY RELATIONSHIPS OF PYRROLEAMIDINE ANTIVIRAL ANTIBIOTICS. 1. MODIFICATIONS OF THE ALKYLAMIDINE SIDE CHAIN (1980) (2)
- Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic Patients (2002) (1)
- Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance (2022) (1)
- Pharmacokinetic and pharmacodynamic analysis of (2S,3S)‐sec‐butylpropylacetamide (SPD) in rats and pigs—A CNS‐active stereoisomer of SPD (2020) (1)
- The borderland of epilepsy: Chairs' Symposium, 10th European Congress on Epileptology, London--October 1, 2012. Introduction. (2012) (1)
- Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. (1985) (1)
- Introduction (2012) (1)
- Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. (2003) (1)
- An unusual cleavage of ring D in Δ14-17-keto steroid after a reaction with alkaline hydrogen peroxide (1981) (1)
- Pharmacokinetic analysis of valdice — a diethylcarbonate prodrug of valproic acid (1994) (1)
- An alternative method for calculating simple pharmacokinetic parameters for zero-order absorption and first-order elimination processes. (1981) (1)
- Theophylline sustained release. (1986) (1)
- FC27 comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity (1994) (0)
- Comparative Activity of the Enantiomers of Fenfluramine and Norfenfluramine in Rodent Seizure Models, and Relationship with their Concentrations in Plasma and Brain. (2023) (0)
- Comprime de theophylline a liberation soutenue (1986) (0)
- STRUCTURE-ACTIVITY RELATIONSHIPS OF PYRROLE AMIDINE ANTIVIRAL ANTIBIOTICS. 2. REPARATION OF MONO- AND TRIPYRROLE DERIVATIVES OF CONGOCIDINE (1981) (0)
- Controlled release dosage form of valproic acid (1986) (0)
- Antiepileptic Drugs and neuropathic pain: Comparative analysis of CNS-active derivatives of valproic acid in the (rat) spinal nerve ligation model (2005) (0)
- Use of derivatives of valproic acid amides and 2-valproic acid amides for the treatment and prevention of pain and / or headache (2001) (0)
- Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects (2016) (0)
- Estimation of pharmacokinetic parameters in extravascular multiple dose administration in the one-compartment open body model with equal absorption and elimination first-order rate constants (1983) (0)
- 33. Eslicarbazepine Acetate (2015) (0)
- The logical structure and validity of experimental designs in pharmacokinetics and clinical pharmacology (1989) (0)
- Abstracts of papers and posters advanced activities in pharmaceutical care 24th European Symposium on Clinical Pharmacy (1995) (0)
- Saturable Processes Affecting Renal Clearance of Cefixime in Dogs (1986) (0)
- Corrigendum (2018) (0)
- Phenytoin metabolic ratio (PMR) correlates with formation clearance of (S)‐7‐OH‐warfarin (2005) (0)
- STRUCTURE-ACTIVITY RELATIONSHIPS OF PYRROLE AMIDINE ANTIVIRAL ANTIBIOTICS. III: PREPARATION OF DISTAMYCIN AND CONGOCIDINE DERIVATIVES BASED ON 2,5-DISUBSTITUTED PYRROLES (1981) (0)
- Oral Session (O1‐A) (2008) (0)
- Derivatives and pharmaceutical compositions of n-hydroxyalkyltetramethyl cyclopropane carboxamide with antiepileptic and processes for their preparation (2002) (0)
- Book Review: Controlled Drug Bioavailability (1985) (0)
- OP27.04: Novel “alkaline phosphatase‐liver/bone/kidney (ALPL)” gene mutation identified in a case of hypophosphatasia (2014) (0)
- Development and pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans and dogs (1984) (0)
- Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. (1985) (0)
- 2-propylvaleriansäure and 2-propylvalerian-acid amide derivatives and their use as anticonvulsant agent (1994) (0)
- Amide derivatives of valproic acid and 2-valproenoic and their use as anticonvulsants. (1994) (0)
- headache use of derivatives of valproic acid amides and 2-valproinsäureamid for treatment and prevention of pain and / or (2001) (0)
- Valnoctamide-stereoisomeric, segregation a method for their manufacture and their applications and (1998) (0)
- The Absorption , Metabolism , and Excretion of the Novel Neuromodulator RWJ-333369 in Humans (2006) (0)
- Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide (2017) (0)
- Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice. (2013) (0)
- 6. Do new and newly developed antiepileptic drugs have better cognitive profiles? (2010) (0)
- Use of derivatives of valproic acid amides and amides 2-valproenic acid for the treatment or prevention of pain and / or headache disorders. (2001) (0)
- Response: Cannabidiol antiseizure activity and its interactions with clobazam: “It’s déjà vu all over again” Yogi Berra (2020) (0)
- Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment (2023) (0)
- Use of 2,2,3,3-tetramethyl cyclopropane carboxylic acid derivatives for the treatment of psychiatric disorders (2004) (0)
- Introduction (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Meir Bialer?
Meir Bialer is affiliated with the following schools:
